Levetiracetam-induced cutaneous adverse drug reactions were not associated with HLA genes in a small sample of Chinese patients with epilepsy

Levetiracetam (LEV) was first approved by United States Food and Drug Administration (US FDA) in December 1999 and proved to be effective in both partial and generalized epilepsy syndromes either as adjunctive treatment or monotherapy (Berkovic et al., 2007; French and Pedley, 2008). Unlike other antiepileptic drugs (AEDs), LEV has unique structural feature, novel antiepileptic mechanism and also fewer adverse side effects. One of the most common adverse reactions, AEDs-induced cutaneous adverse drug reactions (cADRs), has been less reported in LEV.
Source: Epilepsy Research - Category: Neurology Authors: Source Type: research